60 Degrees Pharmaceuticals (SCTP) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
2 Aug, 2026Strategic focus and mission
Focused on developing and commercializing products for unmet medical needs in vector-borne diseases, especially malaria and babesiosis.
Mission centers on addressing significant gaps in prevention and treatment for these diseases.
Product portfolio and pipeline
ARAKODA (tafenoquine) is FDA-approved for malaria prophylaxis, with commercial launch in 2019 and robust US distribution.
ARAKODA is the only prophylactic therapy protecting against all malaria stages, with no drug resistance and convenient weekly dosing.
Pipeline includes expansion into babesiosis treatment, with orphan drug status and multiple ongoing clinical trials.
Additional products for tick-borne diseases and veterinary indications are in development.
Market opportunity and commercial strategy
US malaria prevention market estimated at $50-70M, with growing commercial revenues and profitability targeted for 2028.
Maximum addressable market through 2035: 450,000 malaria and 350,000 babesiosis patients.
Commercial strategy includes increasing awareness, differentiating ARAKODA, and expanding access via partnerships and eCommerce.
Sales growth achieved with lean investment, despite temporary stock-out in 2025.
Latest events from 60 Degrees Pharmaceuticals
- Three evidence streams target a potential 2027 babesiosis sNDA, pending hospital unblinding.SCTP
Investor presentation - January 2027 hospital-trial results will determine the babesiosis regulatory path.SCTPInvestor update
- Hospital study results are expected in January 2027; FDA discussions are planned.SCTPStudy update
- Label expansion for ARAKODA into babesiosis advances, with pivotal milestones expected by 2028.SCTPH.C. Wainwright 28th Annual Global Investment Conference
- Registering 1.77M shares for resale, with focus on infectious disease therapies and Arakoda expansion.SCTPRegistration filing
- Revenue more than doubled, but losses widened and cash runway remains a major concern.SCTPQ2 2026
- Shareholders will vote on director elections, equity plan expansion, a reverse split, and key governance items.SCTPProxy filing
- Shareholders will vote on director elections, equity plan expansion, a reverse split, and key governance items.SCTPProxy filing
- Label expansion and clinical trials could triple platform value by 2028.SCTPH.C. Wainwright 27th Annual Global Investment Conference